Group 1 - The company, Jiukang Bio, announced the receipt of medical device registration certificates from the Beijing Drug Administration for two products: the fully automatic coagulation analyzer (model MDC7600) and the fully automatic chemiluminescence immunoassay analyzer (model Gi 6000) [1] - The fully automatic coagulation analyzer is designed for quantitative analysis of substances in human samples when used with compatible reagents [1] - The fully automatic chemiluminescence immunoassay analyzer utilizes an indirect chemiluminescence method based on AMPPD and alkaline phosphatase, and is used in clinical settings for qualitative or quantitative detection of analytes in various human samples, including serum, plasma, whole blood, urine, and cerebrospinal fluid [1] Group 2 - The analytes that can be detected by the fully automatic chemiluminescence immunoassay analyzer include vitamins, amino acids, drug concentrations, hormones, myocardial diseases, infectious diseases, autoantibodies, tumor-related antigens, proteins and peptides, kidney diseases, liver diseases, immune function assessments, allergen-related projects, coagulation tests, and other enzyme assays [1]

Core Viewpoint - The company, Jiukang Biological, has received medical device registration certificates for two products, which is expected to enhance its core competitiveness and positively impact future development [1]. Product Development - The company has obtained registration certificates for the following products: - Fully automatic coagulation analyzer (Model MDC7600) - Fully automatic chemiluminescence immunoassay analyzer (Model Gi6000) [1]. Competitive Advantage - The acquisition of these medical device registration certificates enriches the company's product categories, thereby strengthening its core competitiveness [1].

Core Insights - The company, 九强生物 (300406.SZ), has recently received a medical device registration certificate from the Beijing Drug Administration for two products: the fully automated coagulation analyzer (model MDC7600) and the fully automated chemiluminescence immunoassay analyzer (model Gi6000) [1] Product Development - The acquisition of the medical device registration certificate enhances the company's product portfolio [1] - The new products are expected to strengthen the company's core competitiveness [1] Future Outlook - The approval of these medical devices is anticipated to have a positive impact on the company's future development [1]

| 证券代码：300406 | 证券简称：九强生物 | 公告编号：2025-073 | | --- | --- | --- | | 债券代码：123150 | 债券简称：九强转债 | | 北京九强生物技术股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 董事会 北京九强生物技术股份有限公司（以下简称"公司"）于近日收到北京 市药品监督管理局颁发的《医疗器械注册证》，具体情况如下： 2025年9月9日 | 序号 | 产品名称 | 注册证编号 | 注册 类别 | 注册证有效期 | 预期用途 | | --- | --- | --- | --- | --- | --- | | 1 | 全自动凝血分析仪 （型号 MDC7600） | 京 械 注 准 20252220804 | Ⅱ | 自批准之日起 有效期至 2030 年 09 月 04 日 | 与适配试剂配合使用，用于人体样本 中待测物的定量分析。 | | | | | | | 该产品采用基于 AMPPD 和碱性磷酸 酶的间接化学发光法，与配套的检测 | | | | | | | 试剂共同使用，在临床上用于对来 ...

Core Points - The company announced the resignation of Liang Hongjun from multiple positions including Vice Chairman, Director, and General Manager due to work relocation [1] - Following his resignation, Liang Hongjun will no longer hold any positions within the company or its subsidiaries, and his departure has been processed according to relevant regulations [1]

Group 1 - Huaneng Power announced that its shareholder Hunan Energy Group plans to reduce its stake by up to 20.31 million shares, not exceeding 1% of the total share capital [1] - Ankai Bus reported a production of 1,012 buses in August, a year-on-year increase of 68.06%, with sales of 773 buses, up 46.95% year-on-year [1] - Lianhuan Pharmaceutical received a drug registration certificate for Famotidine injection, classified as a Class 3 chemical drug [1][2] Group 2 - Dongrui Co. reported sales of 94,800 pigs in August, generating revenue of 160 million yuan, a month-on-month decrease of 5.48% [3] - Tiancheng Control's subsidiary received a notification for a passenger car seat assembly project, expected to start production in April 2026 [5] - ST Huluwa obtained a drug registration certificate for Cefodizime capsules, a third-generation broad-spectrum cephalosporin [6] Group 3 - Jiulong Biotech announced the resignation of its Vice Chairman and General Manager Liang Hongjun due to work adjustments [8] - Guanhua High-tech's shareholder plans to reduce its stake by up to 17.50 million shares, not exceeding 1% of the total share capital [9] - Hebei Steel received approval to issue bonds totaling up to 10 billion yuan [10] Group 4 - Yunnan Energy Investment's subsidiaries received a total of 309 million yuan in renewable energy price subsidies [12] - Zhenghong Technology reported sales of 16,800 pigs in August, with a revenue of 22.87 million yuan, showing a year-on-year increase in sales volume of 63.31% [14] - Jilin Aodong's subsidiary received a drug registration certificate for a solution used in asthma treatment [16] Group 5 - Aonong Biological reported a 26.84% year-on-year increase in pig sales volume in August, reaching 150,100 pigs [18] - Xingdesheng announced a share repurchase plan with a budget of 15 to 30 million yuan [20] - Yueyang Lin Paper's Chairman Ye Meng resigned due to work adjustments [22] Group 6 - Kangchen Pharmaceutical's controlling shareholder plans to reduce its stake by up to 4.78 million shares, not exceeding 3% of the total share capital [23] - Changchun Yidong's General Manager Liu Xiaodong resigned due to work adjustments [25] - Zhongzai Resources' subsidiary received a government subsidy of 12.75 million yuan [26] Group 7 - Tianyu Biological reported a 41.89% month-on-month increase in sales revenue from pig sales in August [27] - Changfei Optical's shareholder Draka Comteq B.V. reduced its stake from 10% to 5% [27] - Zhongchuan Technology's Chairman Wu Xingwang resigned due to work adjustments [28] Group 8 - Huakang Clean announced a successful bid for a medical service construction project valued at 131 million yuan [29] - Yuegui Co. plans to establish a wholly-owned subsidiary with a registered capital of 100 million yuan [31] - Baisheng Intelligent's Vice General Manager and Board Secretary Huang Lijun resigned for personal reasons [32] Group 9 - Jiangsu Shuntian will change its stock name to "Suhao Fashion" starting September 10, 2025 [34] - Jiahe Meikang's shareholder plans to reduce its stake by up to 1.3759 million shares, not exceeding 1% of the total share capital [35] - Heng Rui Pharmaceutical received approval for clinical trials of HRS-4729 injection [37] Group 10 - Changfei Optical's shareholder plans to reduce its stake by up to 110,000 shares, not exceeding 0.15% of the total share capital [39] - Yutong Bus reported sales of 4,260 vehicles in August, a year-on-year increase of 16.78% [40] - JinkoSolar received 646 million yuan in renewable energy subsidies in August, a 248% increase year-on-year [41] Group 11 - Beijing Lier signed a strategic cooperation agreement with SenseTime and Xiwang Technology for AI collaboration [43] - Gongdong Medical's controlling shareholder plans to reduce its stake by up to 3% [44] - Zhonghuan Hailu terminated its control change plan and resumed trading [46] Group 12 - Longzi Co. reported a tax payment of 22.27 million yuan due to a tax audit [48] - Guoguang Chain's controlling shareholder plans to reduce its stake by up to 2.99% [49] - Guoxin Technology successfully tested a new high-performance chip for automotive electronics [50] Group 13 - GF Securities reported a cumulative increase in borrowings exceeding 20% of its net assets [51] - China Construction Bank's subsidiary plans to increase capital by 3 billion yuan [52] - Jifeng Technology plans to establish a wholly-owned subsidiary with a capital of 50 million yuan [53] Group 14 - Jiantou Energy received approval for a stock issuance plan to specific investors [54] - Shanghai Laishi's executives plan to collectively increase their holdings by at least 6 million yuan [55] - Wencan Co. reported a fire incident at its subsidiary, with no casualties reported [56]

Core Points - Liang Hongjun has resigned from his positions as Vice Chairman, Director, and General Manager of Jiukang Biological due to work relocation [1] - Following the resignation, Liang will no longer hold any position within the company [1] - During the interim period of the General Manager vacancy, Chairman Zou Zuojuan will assume the responsibilities of the General Manager until a new appointment is made [1]

格隆汇9月5日丨九强生物(300406.SZ)公布，公司董事会于近日收到副董事长、董事、总经理梁红军先 生提交的书面辞职报告，梁红军先生因工作调动原因辞去公司副董事长、董事、董事会专门委员会及总 经理职务。辞去上述职务后，梁红军先生不再担任公司任何职务，其在公司子公司的任职，已按照有关 规定同步办理离职手续，之后不再担任公司子公司任何职务。 ...

公司及董事会对梁红军先生在任职期间为公司经营发展和公司董事会工 作作出的重要贡献表示衷心感谢！ 特此公告。 北京九强生物技术股份有限公司董事会 2025年9月5日 北京九强生物技术股份有限公司 关于副董事长、总经理离任的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、 误导性陈述或重大遗漏。 北京九强生物技术股份有限公司（以下简称"公司"）董事会于近日收 到副董事长、董事、总经理梁红军先生提交的书面辞职报告，梁红军先生因 工作调动原因辞去公司副董事长、董事、董事会专门委员会及总经理职务。 辞去上述职务后，梁红军先生不再担任公司任何职务，其在公司子公司的任 职，已按照有关规定同步办理离职手续，之后不再担任公司子公司任何职务。 截至本公告披露日，梁红军先生未持有公司股份。梁红军先生原定任期 至公司第五届董事会届满之日，即自 2023 年 9 月 22 日至 2026 年 9 月 21 日 止，其任职期间不存在未履行的承诺。 根据《中华人民共和国公司法》《公司章程》等相关规定，梁红军先生 的辞职未导致公司董事会成员人数低于法定最低人数，不会影响公司董事会 的正常运行，其辞职报告自送达 ...

Core Viewpoint - Beijing Jiukang Biotechnology Co., Ltd. announces the suspension of the conversion of its convertible bonds "Jiukang Convertible Bonds" (bond code: 123150) during the rights distribution period from August 28, 2025, to September 4, 2025, and will resume conversion on September 5, 2025 [1] Summary by Relevant Sections - The company guarantees the authenticity, accuracy, and completeness of the information disclosed, ensuring no false records, misleading statements, or significant omissions [1] - The suspension of the bond conversion is in accordance with the regulations outlined in the prospectus for the issuance of convertible bonds to unspecified objects [1] - Bondholders are advised to pay attention to the resumption of conversion on the first trading day after the rights distribution registration date [1]